The Medicare GLP-1 Bridge Program is arguably the biggest policy shift in weight loss treatment since Medicare was created. Starting July 1, 2026, millions of Medicare Part D enrollees will be able to access brand-name GLP-1 medications — Wegovy (semaglutide) and Zepbound (tirzepatide) — for just $50 per month out of pocket.
Here are the five things every eligible American should know right now.
1. Eligibility Requires a BMI of 30+ or 27+ With Comorbidities
The rules, as Medicare later published them: BMI 35 or higher; BMI 30 or higher with listed conditions; or BMI 27 or higher with listed conditions. People with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible. Current rules are on medicare.gov and our Bridge guide.
Importantly, this is a Part D benefit — meaning you must be enrolled in a Medicare Part D prescription drug plan. Original Medicare alone (Parts A and B) does not cover outpatient prescription drugs, so if you only have Original Medicare, you will need to enroll in a standalone Part D plan during the next enrollment period.
2. The $50/Month Price Is Real — But It's a Copay, Not the Full Cost
The $50 figure is your monthly out-of-pocket copay. The Bridge is a CMS demonstration under the Secretary's authority, not the Inflation Reduction Act's price negotiation program.
For context, the list price of Wegovy is $1,349 per month, and Zepbound runs about $1,086. The Bridge program represents savings of over 95% for patients.
3. Your Doctor Must Prescribe Through an Approved Channel
Ask your pharmacy whether it fills Bridge prescriptions; medicare.gov has the current process.
Telehealth prescriptions are eligible — you do not need an in-person visit to qualify. However, your provider must document the medical necessity and submit the prescription through your Part D plan's formulary.
4. Compounded Versions Are NOT Covered
This is critical: the Bridge program only covers FDA-approved brand-name medications. Compounded semaglutide and compounded tirzepatide are explicitly excluded. If you are currently using a compounded GLP-1 from a telehealth provider, you cannot transfer that prescription to the Bridge program.
This distinction matters because the FDA has been aggressively cracking down on compounding pharmacies throughout 2025 and 2026. If you are on a compounded version, the Bridge program gives you a path to switch to the FDA-approved brand at an affordable price.
5. Enrollment Opens June 1 — Don't Wait Until July
While the program officially starts dispensing medications on July 1, the enrollment and verification process opens June 1. Given the expected demand — CMS estimates 3.4 million eligible beneficiaries in the first year — early enrollment is strongly recommended.
Your doctor submits a form for approval from Medicare. The Bridge runs outside ordinary Part D plan formularies.
The Bottom Line
The Medicare GLP-1 Bridge is a genuine game-changer for Americans 65 and older who have struggled with obesity. At $50 per month for medications that were previously inaccessible to most Medicare beneficiaries, this program will likely become the largest single driver of GLP-1 adoption in 2026. Start preparing now — the demand will be enormous.